• Publications
  • Influence
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
ABSTRACT Immunotherapy of cancer has been explored for over a century, but it is only in the last decade that various antibody‐based products have been introduced into the management of patients withExpand
  • 214
  • 8
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.
The renal uptake of radiolabeled antibody fragments and peptides is a problem in radioimmunodetection and radioimmunotherapy, especially with intracellular retained radiometals. The aim of this studyExpand
  • 160
  • 8
Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
With the approval of 2 radiolabeled antibody products for the treatment of non-Hodgkin's lymphoma (NHL), radioimmunotherapy (RIT) has finally come of age as a new therapeutic modality, exemplifyingExpand
  • 193
  • 6
  • PDF
Cancer radioimmunotherapy.
Targeting of radionuclides with antibodies, or radioimmunotherapy, has been an active field of research spanning nearly 50 years, evolving with advancing technologies in molecular biology andExpand
  • 56
  • 5
Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy.
This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localizedExpand
  • 313
  • 4
A Novel Facile Method of Labeling Octreotide with 18F-Fluorine
Several methods have been developed to label peptides with 18F. However, in general these are laborious and require a multistep synthesis. We present a facile method based on the chelation ofExpand
  • 163
  • 4
Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
Purpose: Evaluate the efficacy of an SN-38-anti-Trop-2 antibody–drug conjugate (ADC) against several human solid tumor types, and to assess its tolerability in mice and monkeys, the latter withExpand
  • 113
  • 4
  • PDF
Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer
BACKGROUND Standard chemotherapy is associated with low response rates and short progression‐free survival among patients with pretreated metastatic triple‐negative breast cancer. SacituzumabExpand
  • 134
  • 4
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Purpose: Sacituzumab govitecan (IMMU-132) is an antibody–drug conjugate (ADC) targeting Trop-2, a surface glycoprotein expressed on many epithelial tumors, for delivery of SN-38, the activeExpand
  • 102
  • 4
  • PDF
Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
Background:Radiolabelled antibody targeting of cancer is limited by slow blood clearance. Pretargeting with a non-radiolabelled bispecific monoclonal antibody (bsMAb) followed by a rapidly clearingExpand
  • 54
  • 4